You are here

Share:

Multi-specific Chimeric Antigen Receptors Against HIV

Summary
Researchers at NCI and NIAID have developed chimeric antigen receptors (CARs) with high affinity for highly conserved regions of HIV Env glycoprotein. Immunotherapy using these CARs can help treat patients infected with HIV and eliminate emergence of HIV escape variants. The technology is currently available for licensing or co-development.
NIH Reference Number
E-170-2013
Product Type
Keywords
  • CAR, HIV, T-cells, Env glycoprotein
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

The present disclosure is directed to novel CD4-based multi-specific chimeric antigen receptor (CAR) proteins composed of an extracellular targeting moiety containing at least two HIV Env-binding motifs, linked to a transmembrane domain and a cytoplasmic signaling domain. The invention further discloses nucleic acids encoding the novel chimeric antigen receptors to enable their expression in host T cells for treatment of HIV infection and disease. Importantly, CAR-transduced CD8 T cells recognize HIV-infected target cells in MHC independent fashion by binding the highly conserved regions of the HIV Env glycoprotein, thus minimizing the selection of viral escape mutants. Furthermore, the present invention also relates to methods of generating a recombinant CD8 T cells expressing a CAR with a CD4-based targeting moiety that does not confer susceptibility to HIV infection.

Potential Commercial Applications

• Therapy for HIV infection
• Research on antiretroviral infection
• Generate HIV-unsusceptible T cells

Competitive Advantages

• Target highly conserved regions of Env of HIV
• Target non-MHC-expressing HIV-infected cells
• Eliminate emergence of escape HIV variants

Inventor(s)

Steven Rosenberg (NCI), Richard Morgan (NCI), Edward Berger (NIAID), Li Liu (NIAID), Bhavik Patel (NIAID)

Development Stage
Publications

Berger EA et al. [PMID 21242898]

Lagenaur LA et al. "sCD4-17b bifunctional protein..." [Retrovirology. 2010 Feb 16;7:11]

Patent Status
  • U.S. Provisional: U.S. Provisional Patent Application Number 61/908,691, Filed 25 Nov 2013
  • Foreign Filed: Foreign Filed - Patent Application PCT/US2014/067459, Filed 25 Nov 2014
  • Foreign Filed: Australia - Patent Application 2014352638, Filed 25 Nov 2014
  • Foreign Filed: Canada - Patent Application 2930587, Filed 25 Nov 2014
  • Foreign Filed: European - Patent Application 14812376.3, Filed 13 Jun 2016
  • U.S. Patent Filed: U.S. Patent Application Number 15/039,384, Filed 25 May 2016
Therapeutic Area
Posted
Wednesday, October 11, 2017